CRNX News and Press, Crinetics Pharmaceuticals Inc. From 05/04/23

2023-05-04 17:31:44 ET Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q1 GAAP EPS of -$0.85 misses by $0.01 . Revenue of $2.67M (-14.7% Y/Y) beats by $2.43M . For further details see: Crinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01...

Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteria Paltusotine’s Phase 2 study in carcinoid syndrome on track for preliminary da...

2023-03-06 10:13:25 ET Summary Crinetics Pharmaceuticals develops therapeutics for endocrine diseases and tumors. Its lead drug candidate, paltusotine, is undergoing two Phase 3 trials for acromegaly treatment. In acromegaly, the excessive production of growth hormone and insulin-...

Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q4 GAAP EPS of -$0.84 misses by $0.01 . Revenue of $0.71M (-34.3% Y/Y) beats by $0.41M . Unrestricted cash, cash equivalents, and investments totaled $334.4 million as of December 31, 2022, compared to $368.4 mi...

Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 Pending a successful outcome from the PATHFNDR studies, an NDA ...

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023. Detai...

Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials o...

Summary Acromegaly pipeline continues to advance with two Phase 3 readouts scheduled for 2023. FDA's red-light of the CRN04777 Phase 2 study received muted price response. Technicals unsupportive of re-rating for now, hence 2023 will be key year for CRNX. Net-net, we rate CRNX a...

SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinis...

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5 th Annual Evercore ISI HealthCONx Conference being held virtually November 29 &...